DUBLIN, Apr. 29, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/47l86b/global_diabetic) has announced the addition of the "Global Diabetic Nephropathy Market 2014-2018" report to their offering.
http://photos.prnewswire.com/prnh/20130307/600769
Diabetic nephropathy is a disease of the kidney glomerulus, which is caused by high blood sugar. When diabetes damages kidneys, which contain millions of tiny blood vessel clusters (glomeruli) that filter waste from the blood, this results in diabetic nephropathy, which is also known as diabetic kidney disease.
Severe damage can lead to kidney failure or irreversible ESRD, requiring dialysis or a kidney transplant. Hypertension, or high blood pressure, is a complication of diabetes that is believed to contribute most directly to diabetic nephropathy. Treatment to limit progression of diabetic nephropathy involves glycemic control and blood pressure control.
The analysts forecast the Global Diabetic Nephropathy market will grow at a CAGR of 5.19 percent over the period 2013-2018.
This report covers the present scenario and the growth prospects of the Global Diabetic Nephropathy market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various diabetic nephropathy drugs available in the market.
The report, the Global Diabetic Nephropathy Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Diabetic Nephropathy market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Topics Covered:
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
04. Market Research Methodology
05. Introduction
06. Market Landscape
07. Pipeline Snapshot
08. Rate of Incidence and Prevalence
09. Geographical Segmentation
10. Buying Criteria
11. Market Growth Drivers
12. Drivers and their Impact
13. Market Challenges
14. Impact of Drivers and Challenges
15. Market Trends
16. Trends and their Impact
17. Vendor Landscape
18. Key Vendor Analysis
19. Other Reports in this Series
Companies Mentioned:
- Merck & Co. Inc.
- Mitsubishi Tanabe Pharma Corp.
- Novartis AG
- Sanofi S.A.
- AbbVie Inc.
- Ampio Pharmaceuticals Inc.
- Astellas Pharma Inc.
- Bayer AG
- ChemoCentryx Inc.. Eli Lilly and Co.
- GenKyoTex S.A.
- Glycadia Pharmaceuticals Inc.
- IMMD Inc.
- Mesoblast Ltd.
- NephroGenex Inc.
- Novo Nordisk A/S
- NOXXON Pharma AG
- OncoImmune Inc.
- Pfizer Inc.
- PhytoHealth Corp.
- Questcor Pharmaceuticals Inc.
- Reata Pharmaceuticals Inc.
For more information visit http://www.researchandmarkets.com/research/47l86b/global_diabetic
Media Contact: Laura Wood, +353-1-481-1716, [email protected]
SOURCE Research and Markets
Share this article